Cross-kingdom botanical intelligence platform. Predicts therapeutic compounds across four biological kingdoms — cannabis, marine polysaccharides, fungi, and plant polysaccharides — before physical testing.
NeuroBotanica combines a patented workflow integration methodology with 31 proprietary analytical engines to deliver pharmaceutical-grade therapeutic prediction at accessible price points.
The platform's MPNN model predicts molecular interactions across compound classes with 98.11% accuracy. The dimeric prediction framework generates 21,000+ novel molecular combinations with formation probability, synergy scores, and condition-specific therapeutic potential.
Cannabis is the entry point — not the ceiling. The dispensary pilot and budtender application are the first commercial vertical in a 7-phase expansion reaching pharmaceutical R&D, clinical medicine, and cultivation.
Message Passing Neural Network predicts cross-kingdom molecular interactions. 98.11% GenomePath accuracy. Not a lookup table — a generative model.
Tablet application for Nevada dispensary staff. Evidence-based product recommendations backed by 505+ peer-reviewed studies. Replaces guesswork with science.
Polysaccharide-cannabinoid receptor interaction modeling. Marine, fungal, and plant polysaccharides mapped against cannabinoid and terpene classes.
Every recommendation ranked by evidence quality. Meta-analysis → RCT → cohort → in vitro → traditional use. Fully auditable at every step.
EthnoPath module integrates FPIC-validated traditional knowledge. VeriTrad-verified, consent-logged, attribution-tracked.
RegPath module maps compounds to FDA and DSHEA pathways. GRAS notifications, NDI submissions, clinical trial readiness built in.
The Nevada pilot entry point. Tablet-based recommendation system. $1,200/month per location. Evidence-based guidance for dispensary staff and patients.
Join Nevada PilotAccess to 505+ study database, MPNN predictions, and cross-kingdom synergy models. API access for academic and industry researchers.
Request AccessClinical protocols, patient digital twins, neuropsychiatric therapeutics. PsychePath + ClinPath modules. 3,000+ target US facilities.
Learn MoreRecruiting Nevada dispensaries for the April 2026 pilot launch. Free onboarding. Tablet deployment. Full training included.